<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010893</url>
  </required_header>
  <id_info>
    <org_study_id>FLUVAL P-H-06</org_study_id>
    <nct_id>NCT01010893</nct_id>
  </id_info>
  <brief_title>Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine</brief_title>
  <official_title>Tolerability and Immunogenicity Study of FLUVAL P Monovalent Influenza Vaccine in Adults and Elderly Persons</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fluart Innovative Vaccine Ltd, Hungary</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fluart Innovative Vaccine Ltd, Hungary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the tolerability and immunogenicity of FLUVAL P monovalent influenza vaccine in&#xD;
      adults and elderly people, with the objective to verify efficacy and tolerability of the&#xD;
      study drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To assess tolerability/safety (incidence of adverse events) of the study drug. To assess the&#xD;
      efficacy (immunogenicity) of the study drug by serology testing of blood samples taken at Day&#xD;
      21-28 after immunization in groups and age groups.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To assess the long-term safety of the study drug 50-60 days after immunization. To determine&#xD;
      the tolerability of simultaneous administration of FLUVAL P monovalent pandemic influenza&#xD;
      vaccine and FLUVAL AB trivalent seasonal influenza vaccine in case of adults and elderly&#xD;
      people.&#xD;
&#xD;
      To assess the efficacy of the study drug by optional epidemiological follow-up of the&#xD;
      participants until the end of the influenza season.&#xD;
&#xD;
      To assess the immunogenicity of the study drug by optional cross-reactive immunity tests&#xD;
      performed with non-homologous influenza A and B virus strains.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post vaccination HI antibody titer</measure>
    <time_frame>21-28 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse reactions</measure>
    <time_frame>21-28 days after vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse reactions</measure>
    <time_frame>50-60 days after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">355</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Influenza vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza vaccination and co-vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination with Fluval P and Fluval AB influenza vaccines</intervention_name>
    <description>Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).</description>
    <arm_group_label>Influenza vaccination and co-vaccination</arm_group_label>
    <other_name>Influenza</other_name>
    <other_name>Pandemic vaccine</other_name>
    <other_name>Seasonal vaccine</other_name>
    <other_name>Co-vaccination</other_name>
    <other_name>Prevention</other_name>
    <other_name>Innfluenza vaccine</other_name>
    <other_name>Influenza in humans</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination with Fluval P monovalent influenza vaccine</intervention_name>
    <description>Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant</description>
    <arm_group_label>Influenza vaccination</arm_group_label>
    <other_name>pandemic</other_name>
    <other_name>influenza</other_name>
    <other_name>prevention</other_name>
    <other_name>vaccine</other_name>
    <other_name>influenza vaccine</other_name>
    <other_name>influenza in humans</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged 18 to 60 years, elderly people aged over 60 years, from both sexes, with&#xD;
             full contractual capacity;&#xD;
&#xD;
          -  Are in good health (as determined by vital signs and existing medical condition) or&#xD;
             are in stable medical condition. Subjects will not be excluded with known adequately&#xD;
             treated clinically significant organ or systemic diseases (e.g. asthma or diabetes),&#xD;
             such that, in the opinion of the investigator, the significance of the disease will&#xD;
             not compromise the subject's participation in the study;&#xD;
&#xD;
          -  Femal volunteers of childbearing potential with a negative result from the urine&#xD;
             pregnancy test prior to vaccination who agrees to use an acceptable contraception&#xD;
             method or abstinence throughout the trial and not become pregnant for the duration of&#xD;
             the study.&#xD;
&#xD;
          -  Capable of understanding and complying with study protocol requirements;&#xD;
&#xD;
          -  The volunteers provide written informed consent prior to initiation of study&#xD;
             procedures;&#xD;
&#xD;
          -  Absence of existence of any exclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding or positive urine pregnancy test at baseline prior to&#xD;
             vaccination;&#xD;
&#xD;
          -  Known allergy to eggs or other components of the vaccine (in particular mercury);&#xD;
&#xD;
          -  History of Guillain-Barré syndrome;&#xD;
&#xD;
          -  Active neoplasm;&#xD;
&#xD;
          -  Immunosuppressive therapy in the preceding 36 months;&#xD;
&#xD;
          -  Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids;&#xD;
&#xD;
          -  Immunoglobulin (or similar blood product) therapy within 3 months prior to&#xD;
             vaccination;&#xD;
&#xD;
          -  Documented HIV, HBV or HCV infection;&#xD;
&#xD;
          -  Chronic illness that, in the opinion of the investigator, may interfere with the&#xD;
             evaluation of the immunoresponse;&#xD;
&#xD;
          -  Acute febrile respiratory illness within one week prior to vaccination;&#xD;
&#xD;
          -  Vaccine therapy within 4 weeks prior to vaccination;&#xD;
&#xD;
          -  Influenza vaccination within 6 months prior to vaccination;&#xD;
&#xD;
          -  Experimental drug therapy within 1 month prior to vaccination;&#xD;
&#xD;
          -  Past or current psychiatric disease of the volunteer that upon judgement of the&#xD;
             investigator may have effect on the objective decision-making of the volunteer;&#xD;
&#xD;
          -  Alcohol or drug abuse of the participant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ferenc Tamas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pilisvorosvar District Doctor's Office</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Osi, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Omninvest Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>District Doctor's Office</name>
      <address>
        <city>Pilisvorosvar</city>
        <zip>H-2085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fourmed Kft. Gyogyhaz</name>
      <address>
        <city>Veszprem</city>
        <zip>H-8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>November 7, 2009</study_first_submitted>
  <study_first_submitted_qc>November 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2009</study_first_posted>
  <last_update_submitted>May 18, 2012</last_update_submitted>
  <last_update_submitted_qc>May 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pandemic</keyword>
  <keyword>prevention</keyword>
  <keyword>influenza</keyword>
  <keyword>infection</keyword>
  <keyword>influenza vaccine</keyword>
  <keyword>vaccine</keyword>
  <keyword>influenza in humans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

